Recombinant human granulocyte macrophage colony stimulating factor in deep second-degree burn wound healing

Yan, Dexiong; Liu, Sha; Zhao, Xiaochun; Bian, Huijuan; Yao, Xingwei; Xing, Ji-Ping; Sun, Weijing; Chen, Xiangjun

doi:10.1097/md.0000000000006881

Cited by 31 publications

(22 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several other innovative therapies for burn wound treatment have also been proposed, among which is the use of recombinant proteins [96], such as elastin-like polypeptides [97]. Elastin is a biocompatible natural human skin component with structural functions [97].…”

Section: Tissue Engineeringmentioning

confidence: 99%

New Nanotechnologies for the Treatment and Repair of Skin Burns Infections

Souto

Ribeiro

Ferreira

et al. 2020

IJMS

View full text Add to dashboard Cite

Burn wounds are highly debilitating injuries, with significant morbidity and mortality rates worldwide. In association with the damage of the skin integrity, the risk of infection is increased, posing an obstacle to healing and potentially leading to sepsis. Another limitation against healing is associated with antibiotic resistance mainly due to the use of systemic antibiotics for the treatment of localized infections. Nanotechnology has been successful in finding strategies to incorporate antibiotics in nanoparticles for the treatment of local wounds, thereby avoiding the systemic exposure to the drug. This review focuses on the most recent advances on the use of nanoparticles in wound dressing formulations and in tissue engineering for the treatment of burn wound infections.

show abstract

Section: Tissue Engineeringmentioning

confidence: 99%

New Nanotechnologies for the Treatment and Repair of Skin Burns Infections

Souto

Ribeiro

Ferreira

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…GM-CSF delivery with an alginate dressing was trialled in chronic ulcers, 80 and a GM-CSF-gelatin hydrogel accelerated closure of partial thickness burns when applied daily. [81][82][83] The appearance of established scars was also improved following 12 weeks of twice daily treatment with rhTGF-b3 in a silicone-hyaluronate cream. 84 GF and cytokine delivery systems therefore offer potential as therapies for cutaneous wound indications.…”

Section: Gfs and Cytokines In The Treatment Of Human Wound Indicationsmentioning

confidence: 95%

Advancements in the Delivery of Growth Factors and Cytokines for the Treatment of Cutaneous Wound Indications

Berry-Kilgour

Cabral

Wise

2021

Advances in Wound Care

View full text Add to dashboard Cite

Wound healing involves the phasic production of growth factors (GFs) and cytokines to progress an acute wound to a resolved scar. Dysregulation of these proteins contributes to both wound chronicity and excessive scarring. Direct supplementation of GFs and cytokines for treatment of healing and scarring complications has, however, been disappointing. Failings likely relate to an inability to deliver recombinant proteins at physiologically relevant levels to an environment conducive to healing. Recent Advances: Inspired by the extracellular matrix, natural biomaterials have been developed that resemble human skin, and are capable of delivering bioactives. Hybrid biomaterials made using multiple polymers, fabrication methods, and proteins are proving efficacious in animal models of acute and impaired wound healing. Critical Issues: For clinical translation, these delivery systems must be tailored for specific wound indications and the correct phase of healing. GFs and cytokines must be delivered in a controlled manner that will target specific healing or scarring impairments. Preclinical assessment in clinically relevant animal models of impaired or excessive healing is critical. Future Directions: Clinical success will likely depend on the GF or cytokine selected, their compatibility with the chosen biomaterial(s), degradation rate of the fabricated system, and the degree of control over release kinetics. Further testing is essential to assess which wound indications are most suited to specific delivery systems and to prove whether they provide superior efficacy over direct protein therapies.

show abstract

“…In clinical practice, recombinant GM-CSF preparations are used in combination with chemotherapy and radiotherapy in the treatment of cancer patients [ 2 ] or in bone marrow transplantation in order to reduce the risk of infections [ 3 ]. In addition, the possibility of using GM-CSF in the treatment of neurodegenerative diseases [ 4 , 5 , 6 ], immunotherapy of malignant diseases [ 7 , 8 ], and in autoimmune conditions [ 9 , 10 ] to accelerate wound healing [ 11 , 12 , 13 ] has recently been investigated.…”

Section: Introductionmentioning

confidence: 99%

Construction of Recombinant Human GM-CSF and GM-CSF-ApoA-I Fusion Protein and Evaluation of Their Biological Activity

et al. 2021

View full text Add to dashboard Cite

In this study, two strains of the yeast P. pastoris were constructed, one of which produced authentic recombinant human granulocyte-macrophage colony-stimulating factor (ryGM-CSF), and the other was a chimera consisting of ryGM-CSF genetically fused with mature human apolipoprotein A-I (ApoA-I) (ryGM-CSF-ApoA-I). Both forms of the cytokine were secreted into the culture medium. The proteins’ yield during cultivation in flasks was 100 and 60 mg/L for ryGM-CSF and ryGM-CSF-ApoA-I, respectively. Both forms of recombinant GM-CSF stimulated the proliferation of human TF-1 erythroleukemia cells; however, the amount of chimera required was 10-fold that of authentic GM-CSF to induce a similar proliferative effect. RyGM-CSF exhibited a 2-fold proliferative effect on BFU-E (burst-forming units—erythroid) at a concentration 1.7 fold less than non-glycosylated E. coli-derived GM-CSF. The chimera together with authentic ryGM-CSF increased the number of both erythroid precursors and BMC granulocytes after 48 h of incubation of human bone marrow cells (BMCs). In addition, the chimeric form of ryGM-CSF was more effective at increasing the viability of the total amount of BMCs, decreasing apoptosis compared to the authentic form. ryGM-CSF-ApoA-I normalized the proliferation, maturation, and segmentation of neutrophils within the physiological norm, preserving the pool of blast cells under conditions of impaired granulopoiesis. The chimera form of GM-CSF exhibited the properties of a multilinear growth factor, modulating the activity of GM-CSF and, perhaps, it may be more suitable for the normalization of granulopoiesis.

show abstract

Recombinant human granulocyte macrophage colony stimulating factor in deep second-degree burn wound healing

Cited by 31 publications

References 15 publications

New Nanotechnologies for the Treatment and Repair of Skin Burns Infections

New Nanotechnologies for the Treatment and Repair of Skin Burns Infections

Advancements in the Delivery of Growth Factors and Cytokines for the Treatment of Cutaneous Wound Indications

Construction of Recombinant Human GM-CSF and GM-CSF-ApoA-I Fusion Protein and Evaluation of Their Biological Activity

Contact Info

Product

Resources

About